Abstract |
Full-length Aβ1-42 and Aβ1-40, N-truncated pyroglutamate Aβ3-42 and Aβ4-42 are major variants in the Alzheimer brain. Aβ4-42 has not been considered as a therapeutic target yet. We demonstrate that the antibody NT4X and its Fab fragment reacting with both the free N-terminus of Aβ4-x and pyroglutamate Aβ3-X mitigated neuron loss in Tg4-42 mice expressing Aβ4-42 and completely rescued spatial reference memory deficits after passive immunization. NT4X and its Fab fragment also rescued working memory deficits in wild type mice induced by intraventricular injection of Aβ4-42. NT4X reduced pyroglutamate Aβ3-x, Aβx-40 and Thioflavin-S positive plaque load after passive immunization of 5XFAD mice. Aβ1-x and Aβx-42 plaque deposits were unchanged. Importantly, for the first time, we demonstrate that passive immunization using the antibody NT4X is therapeutically beneficial in Alzheimer mouse models showing that N-truncated Aβ starting with position four in addition to pyroglutamate Aβ3-x is a relevant target to fight Alzheimer's disease.
|
Authors | Gregory Antonios, Henning Borgers, Bernhard C Richard, Andreas Brauß, Julius Meißner, Sascha Weggen, Vladimir Pena, Thierry Pillot, Sarah L Davies, Preeti Bakrania, David Matthews, Janet Brownlees, Yvonne Bouter, Thomas A Bayer |
Journal | Scientific reports
(Sci Rep)
Vol. 5
Pg. 17338
(Dec 02 2015)
ISSN: 2045-2322 [Electronic] England |
PMID | 26626428
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Amyloid beta-Peptides
- Antibodies, Monoclonal, Murine-Derived
- Peptide Fragments
- amyloid beta-protein (1-42)
|
Topics |
- Alzheimer Disease
(drug therapy, immunology)
- Amyloid beta-Peptides
(immunology)
- Animals
- Antibodies, Monoclonal, Murine-Derived
(immunology, pharmacology)
- Disease Models, Animal
- Humans
- Immunization, Passive
(methods)
- Mice
- Peptide Fragments
(immunology)
- Rats
|